Almac Group announces significant expansion in pharmaceutical development capacity

Published: 11-Nov-2015

Will invest £16m to expand its formulation development and testing facilities at Loughborough, UK


Northern Ireland-based Almac Group, a global contract development and manufacturing organisation, has confirmed a £16m investment to expand its formulation and analytical development services to meet demand.

The company has announced the successful conclusion to negotiations to operate a significant proportion of the 70-acre Charnwood Campus in Loughborough, UK – a world-class science, technology and enterprise park.

Almac will occupy the formulation development and analytical testing facilities at the site, which will complement existing development and GMP services offered from its Craigavon headquarters.

The Charnwood facilities were originally designed and built by AstraZeneca as part of its in-house formulation development, clinical manufacturing and analytical testing capabilities.

Almac has now begun recommissioning the facilities with operations focusing initially on expanding both non-potent and potent solid oral dose processing, creating approximately 180 new jobs in the next five years.

Almac expects to have operations up and running in the first quarter of 2017.

Graeme McBurney, Managing Director, Almac Pharma Services, said: 'As we experience increased client demand for our pharmaceutical development and niche commercial manufacturing services, this latest expansion will significantly enhance Almac’s offering, increasing capacity and capability and further demonstrating our continued commitment to support our global clients in the development and manufacturing of their drug products.'

Last year Almac invested £54m to expand its Northern Ireland operations, with a plan to add 348 jobs over five years. Almac already employed more than 2,100 people at its Craigavon headquarters.

Relevant companies

You may also like